Advertisement
American Journal of Kidney Diseases

Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking

Published:April 13, 2018DOI:https://doi.org/10.1053/j.ajkd.2018.01.057
      Among the many adverse effects of tobacco exposure is the increased risk for progression of kidney disease. Individuals with chronic kidney disease (CKD), who already face increased cardiovascular event rates compared to the general population, are at even greater risk if they smoke. Despite these risks and the increased focus on smoking cessation in the general population in recent years, national guidelines have not specifically targeted individuals with CKD. There are similarly sparse data specific to individuals with CKD regarding the safety and efficacy of evidence-based smoking cessation modalities. This review aims to identify the risks of nicotine dependence in individuals with CKD and the potential benefits of smoking cessation; discuss current strategies for smoking cessation, including behavioral and pharmacologic therapies such as varenicline; and extrapolate these interventions to the unique challenges of this population. Much of the data presented stem from evidence for the general population but are described with additional consideration in dosing of nicotine replacement therapy, as well as non-nicotine pharmacotherapy and treatment modality for individuals with CKD.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stewart B.W.
        • Wild C.P.
        World Cancer Report 2014.
        World Health Organization, Geneva, Switzerland2014
        • Lim S.S.
        • Vos T.
        • Flaxman A.D.
        • et al.
        A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.
        Lancet. 2012; 380: 2224-2260
        • Richardson A.
        • Pearson J.
        • Xiao H.
        • Stalgaitis C.
        • Vallone D.
        Prevalence, harm perceptions, and reasons for using noncombustible tobacco products among current and former smokers.
        Am J Public Health. 2014; 104: 1437-1444
        • Inoue-Choi M.
        • Liao L.M.
        • Reyes-Guzman C.
        • Hartge P.
        • Caporaso N.
        • Freedman N.D.
        Association of long-term, low-intensity smoking with all-cause and cause-specific mortality in the National Institutes of Health-AARP Diet and Health Study.
        JAMA Intern Med. 2017; 177: 87-95
        • Xia J.
        • Wang L.
        • Ma Z.
        • et al.
        Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies.
        Nephrol Dial Transplant. 2017; 32: 475-487
        • Longenecker J.C.
        Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.
        J Am Soc Nephrol. 2002; 13: 1918-1927
        • Lhotta K.
        • Rumpelt H.J.
        • Konig P.
        • Mayer G.
        • Kronenberg F.
        Cigarette smoking and vascular pathology in renal biopsies.
        Kidney Int. 2002; 61: 648-654
        • Orth S.R.
        Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function.
        J Am Soc Nephrol. 2004; 15: 58S-63S
        • Orth S.R.
        Smoking–a renal risk factor.
        Nephron. 2000; 86: 12-26
        • Bergman B.C.
        • Perreault L.
        • Hunerdosse D.
        • et al.
        Novel and reversible mechanisms of smoking-induced insulin resistance in humans.
        Diabetes. 2012; 61: 3156-3166
        • Xu H.
        • Huang X.
        • Arnlov J.
        • et al.
        Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4.
        Clin J Am Soc Nephrol. 2014; 9: 690-697
        • van der Vaart H.
        • Postma D.S.
        • Timens W.
        • ten Hacken N.H.
        Acute effects of cigarette smoke on inflammation and oxidative stress: a review.
        Thorax. 2004; 59: 713-721
        • Pecoits-Filho R.
        • Heimbürger O.
        • Bárány P.
        • et al.
        Associations between circulating inflammatory markers and residual renal function in CRF patients.
        Am J Kidney Dis. 2003; 41: 1212-1218
        • Minami J.
        • Ishimitsu T.
        • Matsuoka H.
        Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers.
        Hypertension. 1999; 33: 586-590
        • Poulsen P.L.
        • Ebbehøj E.
        • Hansen K.W.
        • Mogensen C.E.
        Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients.
        Am J Hypertens. 1998; 11: 1093-1099
        • Klag M.J.
        • Whelton P.K.
        • Randall B.L.
        • et al.
        Blood pressure and end-stage renal disease in men.
        N Engl J Med. 1996; 334: 13-18
        • Tozawa M.
        • Iseki K.
        • Iseki C.
        • Kinjo K.
        • Ikemiya Y.
        • Takishita S.
        Blood pressure predicts risk of developing end-stage renal disease in men and women.
        Hypertension. 2003; 41: 1341-1345
        • Hsu C-y
        • McCulloch C.E.
        • Darbinian J.
        • Go A.S.
        • Iribarren C.
        Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.
        Arch Intern Med. 2005; 165: 923-928
        • Peterson J.C.
        • Adler S.
        • Burkart J.M.
        • Greene T.
        • et al.
        • for the Modification of Diet in Renal Disease Study
        Blood pressure control, proteinuria, and the progression of renal disease.
        Ann Intern Med. 1995; 123: 754-762
        • Campese V.
        • Bigazzi R.
        The role of hypertension in the progression of renal diseases.
        Am J Kidney Dis. 1991; 17: 43-47
        • Benck U.
        • Clorius J.
        • Zuna I.
        • Ritz E.
        Renal hemodynamic changes during smoking- effects of adrenoreceptor blockade.
        Eur J Clin Investig. 1999; 29: 1010-1018
        • Orth S.R.
        Smoking--a renal risk factor.
        Nephron. 2000; 86: 12-26
        • Sarnak M.J.
        • Levey A.S.
        • Schoolwerth A.C.
        • et al.
        Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
        Circulation. 2003; 108: 2154-2169
        • Ockene I.S.
        • Miller N.H.
        Cigarette smoking, cardiovascular disease, and stroke : a statement for healthcare professionals from the American Heart Association.
        Circulation. 1997; 96: 3243-3247
        • Chuahirun T.
        • Hudson C.
        • Seipel T.
        • et al.
        Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes.
        Am J Med Sci. 2004; 327: 57-67
        • Raymond C.B.
        • Naylor H.K.
        Smoking cessation in patients with chronic kidney disease.
        CANNT J. 2010; 20: 24-29
        • Schiffl H.
        • Lang S.
        • Fischer R.
        Stopping smoking slows accelerated progression of renal failure in primary renal disease.
        J Nephrol. 2002; 15: 270-274
        • Verbiest M.
        • Brakema E.
        • van der Kleij R.
        • et al.
        National guidelines for smoking cessation in primary care: a literature review and evidence analysis.
        NPJ Prim Care Respir Med. 2017; 27: 2
        • Stead L.F.
        • Koilpillai P.
        • Lancaster T.
        Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation.
        Cochrane Database Syst Rev. 2015; 10: CD009670
      1. Agency for Healthcare Research and Quality. Five Major Steps to Intervention (The "5 A's"). http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/5steps.html. Accessed August 9, 2017.

        • Jamal A.
        • Dube S.R.
        • Malarcher A.M.
        • Shaw L.
        • Engstrom M.C.
        Tobacco use screening and counseling during physician office visits among adults—National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005–2009.
        MMWR Morbid Mortal Wkly Rep. 2012; 61: 38-45
        • Adler N.E.
        • Stead W.W.
        Patients in context–EHR capture of social and behavioral determinants of health.
        N Engl J Med. 2015; 372: 698-701
        • Stead L.F.
        • Buitrago D.
        • Preciado N.
        • Sanchez G.
        • Hartmann-Boyce J.
        • Lancaster T.
        Physician advice for smoking cessation.
        Cochrane Database Syst Rev. 2013; 5: CD000165
        • Solberg L.I.
        • Boyle R.G.
        • Davidson G.
        • Magnan S.
        • Carlson C.L.
        Patient satisfaction and discussion of smoking cessation during clinical visits.
        Mayo Clin Proc. 2001; 76: 138-143
      2. The Tobacco Use and Dependence Clinical Practice Guideline Panel Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report.
        JAMA. 2000; 283: 3244-3254
        • Hughes J.R.
        • Keely J.
        • Naud S.
        Shape of the relapse curve and long-term abstinence among untreated smokers.
        Addiction. 2004; 99: 29-38
        • Norcross J.C.
        • Krebs P.M.
        • Prochaska J.O.
        Stages of change.
        J Clin Psychol. 2011; 67: 143-154
        • Prochaska J.O.
        • DiClemente C.C.
        Stages and processes of self-change of smoking: toward an integrative model of change.
        J Consult Clin Psychol. 1983; 51: 390-395
        • Prochaska J.O.
        • Velicier W.F.
        • Rossi J.S.
        • et al.
        Stages of change and decisional balance for 12 problem behaviors.
        Health Psychol. 1994; 13: 39-46
        • Rollnick S.
        • Miller W.R.
        What is motivational interviewing?.
        Behav Cogn Psychother. 2009; 23: 325-334
        • Lindson-Hawley N.
        • Thompson T.P.
        • Begh R.
        Motivational interviewing for smoking cessation.
        Cochrane Database Syst Rev. 2015; 3: CD006936
        • Parkes G.
        • Greenhalgh T.
        • Griffin M.
        • Dent R.
        Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial.
        BMJ. 2008; 336: 598-600
      3. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report.
        Am J Prev Med. 2008; 35: 158-176
        • Civljak M.
        • Stead L.F.
        • Hartmann-Boyce J.
        • Sheikh A.
        • Car J.
        Internet-based interventions for smoking cessation.
        Cochrane Database Syst Rev. 2013; 7: CD007078
        • Whittaker R.
        • McRobbie H.
        • Bullen C.
        • Rodgers A.
        • Gu Y.
        Mobile phone-based interventions for smoking cessation.
        Cochrane Database Syst Rev. 2016; 4: CD006611
      4. National Cancer Institute. Quitting is a journey. https://smokefree.gov/. Accessed December 14, 2017.

      5. American Lung Association. Freedom from smoking. http://www.lung.org/stop-smoking/join-freedom-from-smoking/. Accessed August 8, 2017.

        • Schnoll R.A.
        • Patterson F.
        • Wileyto E.P.
        • et al.
        Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial.
        Ann Intern Med. 2010; 152: 144-151
        • Chaiton M.
        • Diemert L.
        • Cohen J.E.
        • et al.
        Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers.
        BMJ Open. 2016; 6: e011045
        • Harris K.K.
        • Zopey M.
        • Friedman T.C.
        Metabolic effects of smoking cessation.
        Nat Rev Endocrinol. 2016; 12: 299-308
        • Farley A.C.
        • Hajek P.
        • Lycett D.
        • Aveyard P.
        Interventions for preventing weight gain after smoking cessation.
        Cochrane Database Syst Rev. 2012; 1: CD006219
        • Stead L.F.
        • Perera R.
        • Bullen C.
        • et al.
        Nicotine replacement therapy for smoking cessation.
        Cochrane Database Syst Rev. 2012; 11: CD000146
        • Cahill K.
        • Stevens S.
        • Perera R.
        • Lancaster T.
        Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
        Cochrane Database Syst Rev. 2013; 5: CD009329
        • Manley H.J.
        • Stack N.M.
        Smoking cessation therapy considerations for patients with chronic kidney disease.
        Nephrol Nurs J. 2008; 35: 357-364
        • Worrall S.P.R.
        • Almond M.K.
        • Dhillon S.
        Pharmacokinetics of bupropion and its metabolites in hemodialysis patients who smoke.
        Nephron Clin Pract. 2004; 97: 83-89
        • Turpeinen M.
        • Koivuviita N.
        • Tolonen A.
        • et al.
        Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.
        Br J Clin Pharmacol. 2007; 64: 165-173
      6. Varenicline [medication guide]. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021928s012s013lbl.pdf. Accessed August 4, 2017.

        • Anthenelli R.M.
        • Benowitz N.L.
        • West R.
        • et al.
        Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
        Lancet. 2016; 387: 2507-2520
        • Kroenke K.
        • Spitzer R.L.
        • Williams J.B.W.
        The PHQ-9 Validity of a Brief Depression Severity Measure.
        J Gen Intern Med. 2001; 16: 606-613
        • Steinberg M.B.
        • Greerhaus S.
        • Schmelzer A.C.
        • et al.
        Triple-combination pharmacotherapy for medically ill smokers- a randomized trial.
        Ann Intern Med. 2009; 150: 447-455
        • Hajek P.
        • Smith K.M.
        • Dhanji A.-R.
        • McRobbie H.
        Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomized controlled trial.
        BMC Med. 2013; 11: 1-7
        • Ebbert J.O.
        • Hatsukami D.K.
        • Croghan I.T.
        • et al.
        Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.
        JAMA. 2014; 311: 155-163
        • Zalai D.
        • Szeifert L.
        • Novak M.
        Psychological distress and depression in patients with chronic kidney disease.
        Semin Dial. 2012; 25: 428-438
        • Kimmel P.L.
        • Cukor D.
        • Cohen S.D.
        • Peterson R.A.
        Depression in end-stage renal disease patients: a critical review.
        Adv Chronic Kidney Dis. 2007; 14: 328-334
        • Cukor D.
        • Coplan J.
        • Brown C.
        • et al.
        Anxiety disorders in adults treated by hemodialysis: a single-center study.
        Am J Kidney Dis. 2008; 52: 128-136
        • Hartmann-Boyce J.
        • McRobbie H.
        • Bullen C.
        • Begh R.
        • Stead L.F.
        • Hajek P.
        Electronic cigarettes for smoking cessation.
        Cochrane Database Syst Rev. 2016; 9: CD010216
        • Bullen C.
        • Howe C.
        • Laugesen M.
        • et al.
        Electronic cigarettes for smoking cessation: a randomised controlled trial.
        Lancet. 2013; 382: 1629-1637
        • Kalkhoran S.
        • Glantz S.A.
        E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis.
        Lancet Respir Med. 2016; 4: 116-128
        • Farsalinos K.E.
        • Kistler K.A.
        • Gillman G.
        • Voudris V.
        Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins.
        Nicotine Tob Res. 2015; 17: 168-174
        • Chapman A.B.
        • Johnson A.M.
        • Gabow P.A.
        • Schrier R.W.
        Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.
        J Am Soc Nephrol. 1994; 5: 1349-1354
        • Ward M.
        • Studenski S.
        Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking.
        Arch Intern Med. 1992; 152: 2082-2088
        • Foley R.N.
        • Herzog C.A.
        • Collins A.J.
        Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study.
        Kidney Int. 2003; 63: 1462-1467
        • Stengel B.
        • Couchoud C.
        • Cénée S.
        • Hémon D.
        Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies.
        Kidney Int. 2000; 57: 2519-2526
        • Grams M.E.
        • Coresh J.
        • Segev D.L.
        • Kucirka L.M.
        • Tighiouart H.
        • Sarnak M.J.
        Vascular disease, ESRD, and death: interpreting competing risk analyses.
        Clin J Am Soc Nephrol. 2012; 7: 1606-1614
        • Ricardo A.C.
        • Anderson C.A.
        • Yang W.
        • et al.
        Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.
        Am J Kidney Dis. 2015; 65: 412-424
        • Staplin N.
        • Haynes R.
        • Herrington W.G.
        • et al.
        Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP).
        Am J Kidney Dis. 2016; 68: 371-380
      7. The Royal Australian College of General Practitioners Ltd. Supporting smoking cessation: a guide for for health professionals. 2014; http://www.racgp.org.au/your-practice/guidelines/smoking-cessation/. Accessed August 8, 2017.

      8. CAN-ADAPTT. Canadian Smoking Cessation Clinical Practice Guideline. https://www.nicotinedependenceclinic.com/English/CANADAPTT/Documents/CAN-ADAPTT Canadian Smoking Cessation Guideline_website.pdf. Accessed August 8, 2017.

      9. Ministry of Health. Background and Recommendations of the New Zealand Guidelines for Helping People to Stop Smoking. 2014; https://www.health.govt.nz/system/files/documents/publications/background-recommendations-new-zealand-guidelines-for-helping-stop-smoking-mar15-v2.pdf. Accessed August 8, 2017.

      10. Friend J, Bery J, Gierson T, et al. A guide to smoking cessation in Scotland 2010: Planning and providing specialist smoking cessation services. 2017. http://www.healthscotland.scot/media/1096/a-guide-to-smoking-cessation-in-scotland-2017.pdf. Accessed August 8, 2017.

        • van Zyl-Smit R.N.
        • Allwood B.
        • Stickells D.
        • et al.
        South African tobacco smoking cessation clinical practice guideline.
        S Afr Med J. 2013; 103: 869-876
        • West R.
        • McNeill A.
        • Raw M.
        Smoking cessation guidelines for health professionals- an update.
        Thorax. 2000; 55: 987-999
        • Siu A.L.
        Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force Recommendation Statement.
        Ann Intern Med. 2015; 163: 622-634